McMaster University

McMaster University

Michael Trus


Associate Professor, Pathology and Molecular Medicine

Division: Clinical Pathology

Associate Member, Department of Oncology

Juravinski Hospital
2nd Floor Lab (F2) Rm 203
905-527-4322 ext. 42737

Assistants:Nautasha Hoyle

Michael Trus

Faculty Biography

Education and Professional Standing

  • PhD, University of Toronto, 2006
  • Hematology, University of Ottawa, 1998
  • Internal Medicine, University of Ottawa, 1997
  • MD, Dalhousie University, 1990


Research Focus

Dr. Trus' research interests include investigating the role of aberrant gene expression in the pathogenesis of acute myelogenous leukemia and therapeutic measures that restore normal gene expression in this disease.

Clinical Focus

Dr. Trus is involved in treatment of patients with malignant blood disorders with special interests in the management of acute myelogenous leukemia. Dr. Trus provides service through the Hamilton Regional Laboratory Medicine Program where he is involved in the interpretation of peripheral blood, bone marrow and flow cytometry samples. 

Academic Interests

Dr. Trus is involved in the education of residents through the Department of Pathology and Division of Hematology.  He is coordinator of the cell diagnostics rotations within the adult Hematology Residency Program. He is also actively involved in the Undergraduate (M.D.) and Postgraduate Medicine Educational Programs. 

Team Members

Research Laboratory Assistant

Ying Lin

Selected Publications

  • San-Marina S, Han Y, Suarez Saiz F, Trus MR, Minden MD. Lyl1 interacts with CREB1 and alters expression of CREB1 target genes. Biochem Biophys Acta. 2008 Mar; 1783(3):503-517.  
  • Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, and Minden MD. This histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia. 2005:1-8.
  • Trus MR, Bordeleau L, Pihl C, McGeer A, Prevost J, Minden MD, Brown CB. Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies. Br J Haematol. 2003 Apr;121(1):86-93.
  • Schimmer AD, Hedley DW, Chow S, Pham NA, Chakrabartty A, Bouchard D, Mak TW, Trus MR, Minden MD. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 2001 Jul;8(7):725-33.
  • Trus MR, Cyr PV, Yang WH, Drouin MA, Goldstein R. Study of the HLA-DQA1*0102 Allele and Ragweed Allergy in Multilplex Families. Cdn J Allergy & Clin Immun. 1999;4:114-116.
  • Kuk JS, MacEachern JA, Soamboonsrup P, McFarlane A, Benger A, Patterson W, Yang L, Trus MR. Chronic Eosinophilic Leukemia Presenting with Autoimmune Hemolytic Anemia and Erythrophagocytosis by Eosinophils. Am J Hematology. 2006; 81:445-461.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0